Edition:
United Kingdom

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

38.30USD
7:05pm BST
Change (% chg)

$0.20 (+0.52%)
Prev Close
$38.10
Open
$38.00
Day's High
$38.40
Day's Low
$37.70
Volume
32,812
Avg. Vol
270,482
52-wk High
$42.80
52-wk Low
$14.40

Chart for

About

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery... (more)

Overall

Beta: 2.13
Market Cap(Mil.): $893.29
Shares Outstanding(Mil.): 54.14
Dividend: --
Yield (%): --

Financials

  HRTX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -4.25 -- --
ROI: -249.61 1.78 14.61
ROE: -298.78 3.28 16.33

BRIEF-Heron Therapeutics Reports Quarterly Loss Per Share Of $0.81

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS

10 May 2018

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

29 Mar 2018

BRIEF-Heron Therapeutics Announces Proposed Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

28 Mar 2018

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

19 Mar 2018

BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

27 Feb 2018

Competitors

Earnings vs. Estimates